Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
71 studies found for:    "gaucher disease"
Show Display Options
Rank Status Study
21 Recruiting Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C
Conditions: Gaucher Disease;   Hepatitis C
Intervention:
22 Active, not recruiting A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
Condition: Gaucher Disease
Intervention: Drug: eliglustat tartrate
23 Approved for marketing Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
24 Completed
Has Results
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Biological: VPRIV ®,
25 Completed
Has Results
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase
Condition: Gaucher Disease, Type 1
Intervention: Biological: GA-GCB (velaglucerase alfa)
26 Completed
Has Results
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Condition: Gaucher Disease, Type 1
Interventions: Biological: velaglucerase alfa;   Biological: imiglucerase
27 Completed
Has Results
Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
Condition: Gaucher Disease, Type 1
Intervention: Drug: GA-GCB
28 Active, not recruiting
Has Results
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
Condition: Gaucher Disease, Type 1
Interventions: Drug: Eliglustat tartrate;   Drug: Imiglucerase
29 Suspended Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease
Condition: Type I Gaucher Disease
Intervention: Drug: Ambroxol
30 Completed
Has Results
Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease
Condition: Type 1 Gaucher Disease
Intervention: Drug: miglustat
31 Recruiting Biomarker for Gaucher Disease
Conditions: Lysosomal Storage Diseases;   Gaucher Disease;   Sphingolipidoses
Intervention:
32 Completed A Long-Term Extension Study of AT2101 in Type 1 Gaucher Patients
Conditions: Gaucher Disease;   Type 1 Gaucher Disease;   Gaucher Disease, Type 1
Intervention: Drug: AT2101
33 Recruiting Home Therapy With VPRIV in Gaucher's Disease
Condition: Gaucher's Disease
Intervention:
34 Completed A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Taliglucerase alfa
35 Completed
Has Results
Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Biological: velaglucerase alfa
36 Completed Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: velaglucerase alfa
37 Unknown  The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease
Condition: Gaucher Disease
Interventions: Drug: Cerezyme®;   Drug: ISU302
38 Completed A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease
Intervention:
39 Completed
Has Results
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
40 Completed A Study of Oral AT2101 in Treatment-naive Patients With Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Drug: AT2101

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years